Do hospitalists overuse proton pump inhibitors? Data from a contemporary cohort
Proton pump inhibitors (PPIs) are commonly used to treat acid‐related disorders but are associated with an increased risk of pneumonia and Clostridium difficile‐associated diarrhea.[1, 2] Initiation of PPIs in hospitalized patients should therefore be limited to specific clinical situations, such as upper gastrointestinal bleeding or stress ulcer prophylaxis in the critically ill.[3] Prior studies suggest significant overuse of PPIs in hospitalized patients exists,[4, 5, 6, 7] but these were published before the widespread implementation of local and national quality improvement efforts targeted at reducing PPI use in medical inpatients (eg, Society of Hospital Medicine's Choosing Wisely list[8]). We aimed to determine the frequency of inappropriate use of PPIs in a contemporary cohort of hospitalized patients in a tertiary care academic medical center. We conducted a retrospective cohort study of 297 patients admitted to a tertiary care center hospitalist service comprised of teaching and nonteaching medical patients who were not critically ill, were admitted between January 1, 2012 and March 31, 2012, and received a PPI during their hospital stay. Three internists used American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy and prior studies to develop criteria to identify appropriate and inappropriate PPI use (Table 1).[4, 5, 6, 7] Appropriate indications included gastrointestinal (GI) bleeding, esophagitis, gastritis, gastroesophageal reflux (GERD), and continuation of home PPI (abrupt discontinuation can trigger reflux symptoms).[9] We extracted the medical records of included patients, applying our prespecified criteria to determine whether use was appropriate. In patients in whom PPI was a continued home medication, we also extracted 2 years of data prior to the index date to determine if the medication was started during a prior hospital admission and, if so, whether this initiation was appropriate. We used descriptive statistics and [2] tests to compare patient characteristics and indications for PPI use. NOTE: Developed from guidelines of the American College of Gastroenterology, American Society for Gastrointestinal Endoscopy, and prior studies.[4, 6] Abbreviations: DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; H pylori, Helicobacter pylori; NSAID, nonsteroidal anti‐inflammatory drug; PPI, proton pump inhibitor. Of 297 patients, the mean age was 64.4 years (standard deviation 16.3 years), most were white (69%), and 56% were women (Table 2). PPI use was appropriate in 231 (78%, 95% confidence interval: 72.6%‐82.4%) patients. Of these, a majority (172, 75%) of patients received a PPI because it was a continued home medication. Only 40 of the 172 patients had the medication started during a recent hospitalization, and in half of those cases (20) the PPI use was appropriate. NOTE: Abbreviations: AST, acid suppressive therapy; NSAID, nonsteroidal anti‐inflammatory drug; PPI, proton pump inhibitor; SD, standard deviation. The second most common appropriate diagnosis was GERD (31%), followed by history of GI bleeding (19%) and treatment for esophagitis or gastritis (18%). Among the 66 patients receiving a PPI inappropriately, the majority of patients (56%) had no documented reason for PPI use, and only 11 patients (17%) were receiving PPI for stress ulcer prophylaxis (Figure 1). Five patients (8%) were treated prophylactically because of steroid or anticoagulant use. We observed no differences in age, gender, race, or reason for admission between the patients treated appropriately versus inappropriately. In a contemporary cohort, chronic PPI use prior to admission was the most common reason PPIs were prescribed in the hospital. About 20% of hospitalized patients were started on a PPI for an inappropriate indication, the majority of whom lacked documentation concerning the reason for use. Among patients treated inappropriately, 36% were discharged on acid‐suppressive therapy. The prior literature has reported a much higher percentages of unnecessary PPI use in hospitalized patients.[4, 5, 6, 7] Gupta et al. found that 70% of patients admitted to an internal medicine service received acid‐suppressive therapy, 73% of whom were treated unnecessarily.[5] Similarly, Nardino et al. found that 65% of acid‐suppressive therapy in hospitalized medical patients was not indicated.[4] If we had excluded patients on home PPIs from our study cohort, we would have found a higher rate of inappropriate use due to a smaller overall patient population. However, we chose to include these patients because they represented the vast majority of hospitalist‐prescribed PPIs. Notably, most of these prior prescriptions were not written during a recent hospital stay, indicating that the majority were initiated by outpatient physicians. Our study is limited by its small sample size, single‐center design, and inability to determine the indications for outpatient PPI use. Still, it has important implications. Prior work has suggested that focusing efforts on PPI overuse may be premature in the absence of valid risk‐prediction models defining the patient populations that most benefit from PPI therapy.[10] Our work additionally suggests that hospital rates of inappropriate initiation may be relatively low, perhaps because hospitalist culture and practice have been affected by both local and national quality improvement efforts and by evidence dissemination.[8] Quality improvement efforts focused on reducing inpatient PPI use are likely to reveal diminishing returns, as admitting hospitalists are unlikely to abruptly discontinue PPIs prescribed in the outpatient setting.[9] Hospitalists should be encouraged to assess and document the need for PPIs during admission, hospitalization, and discharge processes. However, future efforts to reduce PPI overuse among hospitalized patients should predominately be focused on reducing inappropriate chronic PPI use in the outpatient setting. The authors acknowledge Peter Lindenauer for his comments on an earlier draft of this manuscript. Disclosures: The study was conducted with funding from the Department of Medicine at Baystate Medical Center. Dr. Lagu is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K01HL114745. Drs. Lagu and Albugeaey had full access to all of the data in the study, and they take responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Lagu, Albugeaey, and Seiler conceived of the study. Drs. Albugeaey and Al Faraj acquired the data. Drs. Lagu, Albugeaey, Al Faraj, Seiler, and Ms. Garb analyzed and interpreted the data. Drs. Albugeaey and Lagu drafted the manuscript. Drs. Lagu, Albugeaey, Al Faraj, Seiler, and Ms. Garb critically reviewed the manuscript for important intellectual content. Dr. Albugeaey is a recipient of a scholarship from the Ministry of Higher Education, Kingdom of Saudi Arabia. The authors report no conflicts of interest.METHODS
Appropriate PPI use
Inappropriate PPI use
History of upper GI bleeding
No reason given
Endoscopic evidence of peptic ulcer disease
Unspecified GI prophylaxis
Esophagitis
Nonspecific abdominal pain
Gastritis and duodenitis
Heartburn (nonchronic)
Eradication of H pylori
Acute pancreatitis
GERD
Anemia
Barrett's esophagus
Heparin use for DVT prophylaxis
Continued on home PPI
Use of aspirin, NSAID, steroids or Coumadin (as a single agent)
Acute esophageal variceal bleeding
NSAID used in patient >65 years‐old
High‐risk groups; combination of 2 or more of aspirin, NSAID, clopidogrel, or Coumadin
RESULTS
Demographics
PPI Not Indicated, N=66
PPI Indicated, N=231
Total=297
Age, y, mean (SD)
62.5
(16.2)
64.9
(16.3)
64.4
(16.3)
Sex, % No.
Female
51.5%
34
56.7%
131
55.6%
165
Male
48.5%
32
43.3%
100
44.4%
132
Race, % No.
Asian
0.0%
0
0.9%
2
0.7%
2
Black
10.6%
7
9.1%
21
9.4%
28
Hispanic
18.2%
12
19.5%
45
19.2%
57
Unknown
0.0%
0
2.2%
5
1.7%
5
White
71.2%
47
68.4%
158
69.0%
205
Insurance, % No.
Insured
95.5%
63
87.4%
202
89.2%
265
Uninsured
0.0%
0
0.9%
2
0.7%
2
Unknown
4.5%
3
11.7%
27
10.1%
30
Service, % No.
Teaching
25.8%
17
32.9%
76
31.3%
93
Nonteaching
74.2%
49
66.7%
154
68.4%
203
Unknown
0.0%
0
0.4%
1
0.3%
1
Chronic disease, % No.
Cardiac disease
16.7%
11
13.4%
31
14.1%
42
Pulmonary disease
16.7%
11
14.7%
34
15.2%
45
Gastrointestinal disease
13.6%
9
19.5%
45
18.2%
54
Hepatic disease
7.6%
5
3.9%
9
4.7%
14
Stroke
1.5%
1
5.2%
12
4.4%
13
Sepsis
12.1%
8
13.0%
30
12.8%
38
Other
33.3%
22
29.4%
68
30.3%
90
PPI status, % No.
Continued home PPI
0.0%
0
74.5%
172
58.1%
172
Started on PPI in hospital
100%
65
25.5%
59
41.9%
124
Discharged on AST, % No.
Yes
36.4%
24
89.6%
207
22.2%
231
PPI
87.5%
21
96.6%
200
95.7%
221
Brand
52.4%
11
59.5%
119
58.8%
130
Generic
47.6%
10
40.5%
81
41.2%
91
H2 blocker
12.5%
3
3.4%
7
4.3%
10
Brand
0.0%
0
71.4%
5
50.0%
5
Generic
100.0%
3
28.6%
2
50.0%
5
Medications, % No.
Aspirin
36.4%
24
43.7%
101
42.1%
125
NSAID
10.6%
4
6.5%
15
6.4%
19
Corticosteroids
13.6%
9
16.9%
39
16.2%
48
Warfarin
0.0%
5
19.0%
44
16.5%
49
Clopidogrel
12.1%
8
10.8%
25
11.1%
33

DISCUSSION
Acknowledgements